Research programme: integrin inhibitors - 3B Pharmaceuticals
Alternative Names: JSM-8757Latest Information Update: 04 Nov 2017
At a glance
- Originator Jerini
- Developer 3B Pharmaceuticals
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in Germany (PO)
- 13 Jan 2014 Preclinical development is ongoing for Solid tumours in Germany